Distinct subcellular localization in the cytosol and apicoplast, unexpected dimerization and inhibition of Plasmodium falciparum glyoxalases.
The ubiquitous glyoxalase system removes methylglyoxal as a harmful by-product of glycolysis. Because malaria parasites have drastically increased glycolytic fluxes, they could be highly susceptible to the inhibition of this detoxification pathway. Here we analysed the intracellular localization, oligomerization and inhibition of the glyoxalases from Plasmodium falciparum. Glyoxalase I (GloI) and one of the two glyoxalases II (cGloII) were located in the cytosol of the blood stages. The second glyoxalase II (tGloII) was detected in the apicoplast pointing to alternative metabolic pathways. Using a variety of methods, cGloII was found to exist in a monomer-dimer equilibrium that might have been overlooked for homologues from other organisms and that could be of physiological importance. The compounds methyl-gerfelin and curcumin, which were previously shown to inhibit mammalian GloI, also inhibited P. falciparum GloI. Inhibition patterns were predominantly competitive but were complicated because of the two different active sites of the enzyme. This effect was neglected in previous inhibition studies of monomeric glyoxalases I, with consequences for the interpretation of inhibition constants. In summary, the present work reveals novel general glyoxalase properties that future research can build on and provides a significant advance in characterizing the glyoxalase system from P. falciparum.
Butenandt Institute for Physiological Chemistry, Ludwig-Maximilians University, Munich, Germany.
Miriam
M
Urscher
Jude M
JM
Przyborski
Masaya
M
Imoto
Marcel
M
Deponte
D001713:Biphenyl Compounds / Q000494:pharmacology; D002850:Chromatography, Gel; D003474:Curcumin / Q000494:pharmacology; D003600:Cytosol / Q000737:chemistry*; D019281:Dimerization; D004791:Enzyme Inhibitors / Q000494:pharmacology; D004987:Ethers / Q000494:pharmacology; D020128:Inhibitory Concentration 50; D007791:Lactoylglutathione Lyase / Q000037:antagonists & inhibitors / Q000737:chemistry / Q000302:isolation & purification / Q000378:metabolism*; D015394:Molecular Structure; D008970:Molecular Weight; D015388:Organelles / Q000737:chemistry*; D010963:Plasmodium falciparum / Q000737:chemistry / Q000201:enzymology*; D015800:Protozoan Proteins / Q000037:antagonists & inhibitors / Q000737:chemistry / Q000302:isolation & purification / Q000378:metabolism*; D013869:Thiolester Hydrolases / Q000037:antagonists & inhibitors / Q000737:chemistry / Q000302:isolation & purification / Q000378:metabolism*; D000099301:Hydroxyacylglutathione Hydrolase
D001713:Biphenyl Compounds; D003474:Curcumin; D004791:Enzyme Inhibitors; D004987:Ethers; D007791:Lactoylglutathione Lyase; D015800:Protozoan Proteins; D013869:Thiolester Hydrolases; D000099301:Hydroxyacylglutathione Hydrolase; C477902:4-carboxy-5,5'-dihydroxy-3,3'-dimethyl-diphenylether